Survival of all 354 Ph- or BCR-ABL–positive CML patients that were eligible for transplantation and genetically randomized according to availability of a related donor. The survival times of patients who received an unrelated transplant in first chronic phase were censored at the day of transplantation. The survival differences were significant for the entire period and for the time until the curves converge (first cut point, year 8) (Wilcoxon-Gehan test: P = .049 and P = .041, respectively). For patients at risk see Table 2. m.s. indicates median survival. The error bars signify 95% confidence intervals.¹⁶